IL1B and atherosclerosis: Anti-inflammation is increasingly recognized as a promising approach to atherosclerosis prevention, with agents such as canakinumab (IL-1β inhibitor) and sodium-glucose co-transporter-2 inhibitors, though their anti-inflammatory effects 89-92.